Description: First Wave BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. First Wave BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.
Home Page: www.firstwavebio.com
FWBI Technical Analysis
777 Yamato Road
Boca Raton,
FL
33431
United States
Phone:
561 589 7020
Officers
| Name | Title |
|---|---|
| Mr. James R. Sapirstein M.B.A., R.Ph. | Pres, CEO & Chairman |
| Dr. James E. Pennington M.D. | Consultant |
| Mr. Martin Krusin M.B.A. | Sr. VP of Corp. Devel. |
| Ms. Sarah Romano CPA | Chief Financial Officer |
| Ms. Amy Chandler-Skerkis | VP of Regulatory Affairs, QA & Compliance |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8181 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2016-10-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 17 |